SAT2 and pachyonychia congenita: Compared to the established markers in PC, such as CA19-9 [18], SAT2’s high diagnostic AUC (0.882) from the TCGA data indicates a superior specificity, though validation in larger, prospective cohorts is needed to confirm its clinical utility over existing tools [19].